CAREER OPPORTUNITIES

ImmuNext develops immunomodulatory compounds on the cutting edge of immunotherapy for cancer and autoimmune diseases. Negative checkpoint regulators are changing the way cancer is treated. Our flagship product, anti-VISTA, is partnered with Johnson & Johnson. We believe that our next product, VISTA-Ig, will establish a new class of compounds for autoimmunity. Our third product is a breakthrough antibody that targets CD40L, the 'holy grail' of autoimmune treatment. Our core competencies are discovery, target biology and pre-clinical drug development.

Due to the volume of applicants, we will only respond directly to candidates whose backgrounds most closely align with the requirements of the position.